Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis
Table 1
Laboratory data on admission.
CBC
Chemistry
Bone marrow
WBC
113,500/μl
LDH
2,162 U/l
NCC
1,30,000/μl
Blasts
83.0%
AST
74 U/l
Megakaryocytes
0.0/μl
Promyelocytes
1.0%
ALT
444 U/l
M/E
11.40
Myelocytes
2.0%
ALP
250 U/l
Blasts
83.8%
Metamyelocytes
2.0%
T-Bil
0.59 mg/dl
Promyelocytes
1.0%
Stabs
0.0%
T-Pro
6.0 g/dl
Myelocytes
1.0%
Segmented
2.0%
Na
139 mEq/l
Metamyelocytes
0.6%
Eosinophils
0.0%
K
4.3 mEq/l
Slabs
1.4%
Basophils
0.0%
Cl
107 mEq/l
Segmented
1.0%
Monocytes
32.0%
BUN
17.9 mg/dl
Eosinophils
0.0%
Lymphocytes
7.0%
Creatinine
1.18 mg/dl
Basophils
0.0%
Reticulocytes
5.5%
CRP
1.2 mg/dl
Monocytes
1.2%
RBC
289 × 104/μl
—
—
Lymphocytes
2.0%
Hemoglobin
8.8 g/dl
—
—
G-banding
46,XY,t(9;22)(q34;q11.2)
PLT
2.1 × 104/μl
—
—
Major bcr/abl mRNA
1.0 × 105 copies/μg RNA
CBC: complete blood cell count, WBC: white blood cells, RBC: red blood cells, PLT: platelets, LDH: lactate dehydrogenase, AST: alanine aminotransferase, ALT: aspartate aminotransferase, ALP: alkaline phosphatase, T-Bil: total bilirubin, T-Pro: total protein, BUN: blood urea nitrogen, CRP: C-reactive protein, NCC: nuclear cell count, and M/E: myeloid to erythroid ratio.